U.S., July 16 -- ClinicalTrials.gov registry received information related to the study (NCT07066969) titled 'Prevalence of Germline Alterations in Actionable Genes in Endometrial Cancer' on July 04.
Brief Summary: Endometrial cancer (EC) is the most common gynecological cancer in developed countries, with 10200 new cases of EC (5.5% of all cancers) estimated in 2023 and 2500 death for EC estimated in 2022 in Italy.
Recently, the classical clinicopathological risk factors, such as age, FIGO stage, myometrial invasion, tumor grade, lymphovascular space invasion, and lymph node status, have been associated with molecular features for EC risk stratification. The recently introduced molecular classification, based on a very relevant publicatio...